Author pages are created from data sourced from our academic publisher partnerships and public sources.
Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn
Abstract Background: Although inhaled nitric oxide (iNO) causes selective pulmonary vasodilation and improves oxygenation in newborn infants with persistent pulmonary hypertension, its effects are… Expand
Inhaled nitric oxide in preterm infants undergoing mechanical ventilation.
BACKGROUND Bronchopulmonary dysplasia in premature infants is associated with prolonged hospitalization, as well as abnormal pulmonary and neurodevelopmental outcome. In animal models, inhaled nitric… Expand
A Phase I/II Trial of High-Dose Erythropoietin in Extremely Low Birth Weight Infants: Pharmacokinetics and Safety
- S. Juul, R. Mcpherson, L. Bauer, Kelly J. Ledbetter, C. Gleason, D. Mayock
- 1 August 2008
OBJECTIVES. High-dose recombinant erythropoietin is neuroprotective in animal models of neonatal brain injury. Extremely low birth weight infants are at high risk for brain injury and… Expand
High-Dose Erythropoietin and Hypothermia for Hypoxic-Ischemic Encephalopathy: A Phase II Trial
OBJECTIVE: To determine if multiple doses of erythropoietin (Epo) administered with hypothermia improve neuroradiographic and short-term outcomes of newborns with hypoxic-ischemic encephalopathy.… Expand
Effects of transfusions in extremely low birth weight infants: a retrospective study.
OBJECTIVES To determine the risks and benefits associated with the transfusion of packed red blood cells (PRBCs) in extremely low birth weight (ELBW) infants. We hypothesized that when ELBW infants… Expand
A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants.
- S. Juul, B. Comstock, +25 authors P. Heagerty
- The New England journal of medicine
- 15 January 2020
BACKGROUND High-dose erythropoietin has been shown to have a neuroprotective effect in preclinical models of neonatal brain injury, and phase 2 trials have suggested possible efficacy; however, the… Expand
Erythropoietin for Neuroprotection in Neonatal Encephalopathy: Safety and Pharmacokinetics
OBJECTIVE: To determine the safety and pharmacokinetics of erythropoietin (Epo) given in conjunction with hypothermia for hypoxic-ischemic encephalopathy (HIE). We hypothesized that high dose Epo… Expand
Outcomes of extremely low birth weight infants given early high-dose erythropoietin
Objective:To evaluate long-term outcomes of 60 extremely low birth weight (ELBW) infants treated with or without three injections of high-dose erythropoietin (Epo).Study Design:A retrospective… Expand
High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL): A Randomized Controlled Trial – Background, Aims, and Study Protocol
Background: Hypoxic-ischemic encephalopathy (HIE) remains an important cause of neonatal death and frequently leads to significant long-term disability in survivors. Therapeutic hypothermia, while… Expand
Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial
Background:Despite therapeutic hypothermia, neonates with encephalopathy (NE) have high rates of death or disability. Darbepoetin alfa (Darbe) has comparable biological activity to erythropoietin,… Expand